Eshleman J R, Markowitz S D
Department of Pathology, University Hospitals of Cleveland, OH, USA.
Hum Mol Genet. 1996;5 Spec No:1489-94. doi: 10.1093/hmg/5.supplement_1.1489.
Mismatch repair defects are carcinogenic. This conclusion comes some 80 years after the original description of a type of familial colorectal cancer in which mismatch repair defects are involved, and from decades of dedicated basic science research into fundamental mechanisms cells use to repair their DNA. Mismatch repair (MMR) was described first in bacteria, later in yeast and finally in higher eukaryotes. In bacteria, one of its roles is the rapid repair of replicative errors thereby providing the genome with a 100-1000-fold level of protection against mutation. It also guards the genome by preventing recombination between non-homologous regions of DNA. The information gained from bacteria suddenly became relevant to human neoplasia in 1993 when the RER phenotype of microsatellite instability was discovered in human cancers and was rapidly shown to be due to defects in mismatch repair. Evidence supporting the role of MMR defects in carcinogenesis comes from a variety of independent sources including: (i) theoretical considerations of the requirement for a mutator phenotype as a step in multistage carcinogenesis; (ii) discovering that MMR defects cause a 'mutator phenotype' destabilizing endogenous expressed genes including those integral to carcinogenesis; (iii) finding MMR defects in the germline of HNPCC kindred members; (iv) finding that such defects behave as classic tumor suppressor genes in both familial and sporadic colorectal cancers; (v) discovering that MMR 'knockout' mice have an increased incidence of tumors; and (vi) discovering that genetic complementation of MMR defective cells stabilizes the MMR deficiency-associated microsatellite instability. Models of carcinogenesis now must integrate the concepts of a MMR defect induced mutator phenotype (Loeb) with the concepts of multistep colon carcinogenesis (Fearon and Vogelstein) and clonal heterogeneity/selection (Nowell).
错配修复缺陷具有致癌性。这一结论是在最初描述一种涉及错配修复缺陷的家族性结直肠癌约80年后得出的,也是经过数十年对细胞修复其DNA的基本机制进行的专门基础科学研究后得出的。错配修复(MMR)最早在细菌中被描述,随后在酵母中,最终在高等真核生物中被描述。在细菌中,它的作用之一是快速修复复制错误,从而为基因组提供100至1000倍水平的抗突变保护。它还通过防止DNA非同源区域之间的重组来保护基因组。1993年,当在人类癌症中发现微卫星不稳定性的RER表型,并迅速证明这是由于错配修复缺陷所致时,从细菌中获得的信息突然与人类肿瘤形成相关。支持MMR缺陷在致癌作用中发挥作用的证据来自多种独立来源,包括:(i)对作为多阶段致癌过程中一个步骤的突变体表型要求的理论思考;(ii)发现MMR缺陷会导致一种“突变体表型”,使包括那些对致癌作用至关重要的内源性表达基因不稳定;(iii)在HNPCC家族成员的种系中发现MMR缺陷;(iv)发现在家族性和散发性结直肠癌中,此类缺陷表现为经典的肿瘤抑制基因;(v)发现MMR“敲除”小鼠的肿瘤发生率增加;以及(vi)发现MMR缺陷细胞的基因互补可稳定与MMR缺陷相关的微卫星不稳定性。现在的致癌模型必须将MMR缺陷诱导的突变体表型(洛布)的概念与多步骤结肠癌致癌作用(费伦和沃格尔斯坦)以及克隆异质性/选择(诺埃尔)的概念整合起来。